Silicon Valley based Glooko, Inc. and Diasend AB (publ), based in Gothenburg, have merged to enable in-clinic and remote diabetes management across 4,000 diabetes health systems, 23 countries and 15 languages worldwide.

Glooko and Diasend are both known for making diabetes management easier by offering diabetes management and analytics platforms that facilitate data driven care for patients and clinicians. The joint platform downloads data from more than 160 different devices, including glucose meters, insulin pumps and activity trackers. Together the joint solution enables support for people with diabetes during and in-between doctor visits, as well as in-office diabetes data uploads and analytics. USD 8 million in equity financing was raised in connection with the transaction from investors such as the venture capital firm Canaan Partners, Samsung Ventures, Social Capital and Yogen Dalal, Glooko’s founder and partner emeritus at the venture capital firm Mayfield fund.

Glooko, Inc. was advised by Mannheimer Swartling and Gunderson Dettmer in the transaction. Mannheimer Swartling’s team primarily included Johan Ljungberg, Emma Olnäs Fors, Magnus Prick and Azra Skorupan (M&A), Hampus Thofte, Marcus Glimberg and Mikaela Källmén (US law), Karin Attorps and Niklas Hagbard (Tax/Incentive program), Nils Gruske (IPR), Louise Bjartell (Regulatory) and Johannes Eklund (Employment).